Haematologica, Vol 92, Issue 9, 1284-1285 doi:10.3324/haematol.10317
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Planelles, L.
Right arrow Articles by Hahne, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Planelles, L.
Right arrow Articles by Hahne, M.

Chronic Lymphocytic Leukemia

APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival

Lourdes Planelles*,, Sonia Castillo-Gutiérrez°, Jan Paul Medema#, Antonio Morales-Luque°, Hélène Merle-Béral@,+, Michael Hahne*,+

* Institut de Génétique Moléculaire de Montpellier, UMR5535, Montpellier, France
° Department of Statistics and Operation Research, University of Jaén, Spain
# Laboratory for Experimental Oncology and Radiobiology, Amsterdam Medical Center, Amsterdam, The Netherlands
@ Service d’Hématologie Biologique, Groupe Hospitalier La Pitié-Salpêtrière, Paris, France

Correspondence: Lourdes Planelles, PhD, Department of Immunology and Oncology, Centro Nacional de Biotecnologia/CSIC, Darwin 3, UAM Campus de Cantoblanco, 28049 Madrid, Spain. Phone: international +34.915854855. Fax: international +34.9.13720493. E-mail: lplanelles{at}cnb.uam.es

APRIL (a proliferation-inducing ligand) and BLyS (B lymphocyte stimulator) expression have been reported in chronic lymphocytic leukemia (CLL) cells. We examined APRIL and BLyS serum levels in CLL patients and evaluated the prognostic significance of APRIL expression on survival.

Key words: LLC, APRIL serum levels, overall survival, prognostic factor.




This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
J Morel, C Roubille, L Planelles, C Rocha, L Fernandez, C Lukas, M Hahne, and B Combe
Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus
Ann Rheum Dis, June 1, 2009; 68(6): 997 - 1002.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
F. C. Kimberley, L. van Bostelen, K. Cameron, G. Hardenberg, J. A. Marquart, M. Hahne, and J. P. Medema
The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking
FASEB J, May 1, 2009; 23(5): 1584 - 1595.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
D. Bonci, M. Musumeci, V. Coppola, A. Addario, C. Conticello, M. Hahne, M. Gulisano, F. Grignani, and R. De Maria
Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity
Haematologica, December 1, 2008; 93(12): 1899 - 1902.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
G. Hardenberg, L. Fernandez, J. Hendriks, K. Chebli, C. Jacquet, M. Sitbon, M. Hahne, and J. P. Medema
APRIL facilitates viral-induced erythroleukemia but is dispensable for T cell immunity and lymphomagenesis
J. Leukoc. Biol., August 1, 2008; 84(2): 380 - 388.
[Abstract] [Full Text] [PDF]